Previous Article | Next Article ![]()
Antimicrobial Agents and Chemotherapy, December 2001, p. 3482-3486, Vol. 45, No. 12
Laboratoire de Bactériologie,
Faculté de Médecine Pitié-Salpêtrière,
Paris 75634, France1; Division of Tuberculosis
Elimination, Centers for Disease Control and Prevention,
Atlanta, Georgia 303332; and Global
Alliance for TB Drug Development, New York, New York
100383
Received 16 July 2001/Returned for modification 20 August
2001/Accepted 20 September 2001
Mice infected with 1.6 × 107 CFU of
Mycobacterium tuberculosis were treated 14 days later
for 6 months with a regimen of once-weekly 10 mg of rifapentine and 75 mg of isoniazid per kg of body weight supplemented with either 150 mg
of streptomycin per kg or 100 mg of moxifloxacin per kg during either
both the 2-week daily initial and once-weekly continuation phases or
only in the daily 2-week initial phase. On completion of treatment, all
lung cultures were negative, except for three mice, each with a single
colony: two whose rifapentine-isoniazid regimen was supplemented with streptomycin during the whole course of therapy and one whose rifapentine-isoniazid regimen had no initial daily phase, but was
supplemented with streptomycin and moxifloxacin during the whole course
of therapy. After 3 months of follow-up, positive lung cultures were
obtained from 61 and 56% of mice supplemented with streptomycin during
either the full course of therapy or only the daily 2-week initial
phase, respectively, and 15 and 50% of mice supplemented with
moxifloxacin during either the full course of therapy or only the daily
2-week initial phase, respectively. These results suggest that
moxifloxacin has sterilizing activity against M.
tuberculosis.
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.12.3482-3486.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Effectiveness of Once-Weekly Rifapentine and Moxifloxacin
Regimens against Mycobacterium tuberculosis in
Mice
*
Corresponding author. Mailing address: Laboratoire de
Bactériologie-Hygiène, Faculté de Médecine
Pitié-Salpêtrière, 91 Boulevard de l'Hôpital,
75634 Paris, Cedex 13, France. Phone: (33) 1 40 77 97 46. Fax: (33) 1 45 82 75 77. E-mail: lounis{at}chups.jussieu.fr.
This article has been cited by other articles:
| Clin. Vaccine Immunol. | Clin. Microbiol. Rev. |
|---|---|
| J. Clin. Microbiol. | ALL ASM JOURNALS |